The safety of cardioselective beta(1)-blockers in asthma: literature review and search of global pharmacovigilance safety reports.
-
アブストラクト INTRODUCTION:Beta-blockers are key in the management of cardiovascular diseases but blocking airway beta(2)-receptors can cause severe and sometimes fatal bronchoconstriction in people with asthma. Although cardioselective beta(1)-blockers may be safer than non-selective beta-blockers, they remain relatively contraindicated and under-prescribed. We review the evidence of the risk associated with cardioselective beta(1)-blocker use in asthma.METHODS:We searched "asthma" AND "beta-blocker" in PubMed and EmbaseOvid from start to May 2020. The World Health Organization (WHO) global database of individual case safety reports (VigiBase) was searched for reports of fatal asthma or bronchospasm and listed cardioselective beta(1)-blocker use (accessed February 2020). Reports were examined for evidence of pre-existing asthma.RESULTS:PubMed and EmbaseOvid searches identified 304 and 327 publications, respectively. No published reports of severe or fatal asthma associated with cardioselective beta(1)-blockers were found. Three large observational studies reported no increase in asthma exacerbations with cardioselective beta(1)-blocker treatment. The VigiBase search identified five reports of fatalities in patients with pre-existing asthma and reporting asthma or bronchospasm during cardioselective beta(1)-blocker use. Four of these deaths were unrelated to cardioselective beta(1)-blocker use. The circumstances of the fifth death were unclear.CONCLUSIONS:There were no published reports of cardioselective beta(1)-blockers causing asthma death. Observational data suggest that cardioselective beta(1)-blocker use is not associated with increased asthma exacerbations. We found only one report of an asthma death potentially caused by cardioselective beta(1)-blockers in a patient with asthma in a search of VigiBase. The reluctance to use cardioselective beta(1)-blockers in people with asthma is not supported by this evidence.ジャーナル名 ERJ open research Pubmed追加日 2021/3/9 投稿者 Bennett, Miriam; Chang, Catherina L; Tatley, Michael; Savage, Ruth; Hancox, Robert J 組織名 Respiratory Research Unit, Dept of Respiratory Medicine, Waikato Hospital,;Hamilton, New Zealand.;New Zealand Pharmacovigilance Centre, Division of Health Sciences, University of;Otago, Dunedin, New Zealand.;Dept of General Practice, University of Otago, Christchurch, New Zealand.;Uppsala Monitoring Centre, Uppsala, Sweden.;Dept of Preventive and Social Medicine, University of Otago, Dunedin, New;Zealand. Pubmed リンク https://www.ncbi.nlm.nih.gov/pubmed/33681344/ -
お問合わせ
検索
メルマガ登録
